This page shows the latest Seattle Generics news and features for those working in and with pharma, biotech and healthcare.
Immunomedics has signed up Seattle Genetics as the licensee for its triple-negative breast cancer (TNBC) drug IMMU-132, getting $300m upfront and another $1.7bn in possible milestone payments. ... Seattle Genetics will handle the running of a proposed
More from news
Approximately 1 fully matching, plus 0 partially matching documents found.
Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...